FCCC LOGO Faculty Publications
Sheng JY , Movva S
Systemic Therapy for Advanced Soft Tissue Sarcoma
Surg Clin North Am. 2016 Oct;96(5) :1141-56
Back to previous list
Abstract
Soft tissue sarcomas are rare tumors that present with distant metastasis in up to 10% of patients. Survival has improved significantly because of advancements in histologic classification and improved management approaches. Older agents such as doxorubicin, ifosfamide, gemcitabine, and paclitaxel continue to demonstrate objective response rates from 18% to 25%. Newer agents such as trabectedin, eribulin, aldoxorubicin, and olaratumab have demonstrated improvements in progression-free survival, overall survival, or toxicity profiles. Future studies on treatment of advanced soft tissue sarcoma will continue to concentrate on reducing toxicity, personalization of therapy, and targeting novel pathways.
Notes
Sheng, Jennifer Y Movva, Sujana Review United States Surg Clin North Am. 2016 Oct;96(5):1141-56. doi: 10.1016/j.suc.2016.06.006.